The Food and Drug Administration has given Lunar 510(k) clearancefor the final pieces of its automated vertebral morphometry techniquefor its Expert-XL bone densitometer. Vertebral morphometry addsinformation about bone size and shape to the bone density
The Food and Drug Administration has given Lunar 510(k) clearancefor the final pieces of its automated vertebral morphometry techniquefor its Expert-XL bone densitometer. Vertebral morphometry addsinformation about bone size and shape to the bone density dataacquired by densitometers.
Lunar's vertebral morphometry application allows clinicians tomake computerized measurements of vertebral dimensions and howthese dimensions change over time, then compare them to a referencebase of a normal population to determine whether the measurementsare abnormal. Lunar's 510(k) clearance was for use of the referencebase and adds to clearances received last year for other partsof the technology.
Automated vertebral morphometry is a major selling point of Expert-XL,according to David Weissburg, marketing manager for the Madison,WI, company. Although the technique is not in widespread clinicaluse, it has promising clinical potential and is commonly usedby pharmaceutical companies developing drugs for the treatmentof osteoporosis.
"It provides a new level of information about bone status,"Weissburg said.
Lunar is offering vertebral morphometry as an option on Expert-XLsystems, and most ship with the option. The company has been shippingthe application to overseas customers since the Expert line waslaunched in 1994, according to Weissburg.
Vertebral morphometry was an issue in a patent dispute last yearbetween Lunar and archrival Hologic of Waltham, MA. The disputewas settled with a patent cross-licensing deal between the companies(SCAN 10/11/95).
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.